Table 2.
Clinical studies with Saporin-based immunotoxins and bispecific antibodies. PR, partial response; MTD, maximum tolerated dose.
| IT/TT | Target Antigen | Disease | No. of Patients | Phase | Comments | Reference |
|---|---|---|---|---|---|---|
| BER-H2/SO6 | CD30 | Hodgkin’s lymphoma | 4 | pilot | 3 PRs | [40] |
| BsAb1 + BsAb2 | CD22 | B-cell lymphoma | 5 | pilot | 4 PRs | [41,42] |
| BU12-Saporin | CD19 | B-cell lymphoma | 8 | I | MTD not reached | Flavell et al. unpublished results (1996) |
| OKT10-Saporin | CD38 | Myeloma | 10 | I | MTD not reached | Flavell et al. unpublished results (2001) |
| BU12-Saporin | CD19 | Pediatric ALL | 5 | I | MTD not reached | Flavell et al. unpublished results (2002) |